Evidence map›Paper›PMID 40634156›Full record

ReviewThe journal of prevention of Alzheimer's disease2025

CTAD taskforce: genetic therapies in Alzheimer's disease.

D Jakabek, A M Isaacs, B De Strooper, M Tuszynski, R Lane, O Uspenskaya, E McDade, M S Rafii, C J Mummery

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Gene and genetic therapies in Alzheimer's disease and other dementias.The journal of prevention of Alzheimer's disease · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

D JakabekUniversity College London, London, UK.
A M IsaacsUniversity College London, London, UK.
B De StrooperUKDRI@ University College London, London, UK and VIB@KULeuven, Belgium.
M TuszynskiUniversity of California San Diego, San Diego, USA.
R LaneIONIS Pharmaceuticals, Carlsbad, USA.
O UspenskayaPrevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company, USA.
E McDadeWashington University in St. Louis, Saint Louis, USA.
M S RafiiUniversity of Southern California, Los Angeles, USA.
C J MummeryUniversity College London, London, UK. Electronic address: cath.mummery@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are an increasing number of genetic approaches to treating Alzheimer's disease and other dementias, with some promising results from early-phase trials. This prompted the convention of the first EU-US CTAD Task Force on genetic therapies in Alzheimer's disease in October 2024. Preclinical studies and clinical trials of genetic therapies in Alzheimer's disease and other dementias are presented here with key lessons for the field. Importantly, there are several challenges and opportunities unique to neurogenetic therapies which were reviewed and discussed, including means of genetic manipulation, adverse events, monitoring, timing of therapy, and the importance of patient involvement in trial design. Continued collaboration across disciplines will accelerate development of neurogenetic therapeutics.

Indexed as

Alzheimer DiseaseGenetic TherapyAdvisory CommitteesClinical Trials as TopicHumansAAVASOGenetic therapyRCTssiRNA

Identifiers

PMID40634156
PMCPMC12413703

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.